Search - tctmd.com

Displaying 421 - 440 of 536

Sort: Relevancy | Date

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

News Daily News

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

May 04, 2017

TCTMD’s Top 10 Most Popular Stories for April 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

April 28, 2017

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

News Daily News

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

April 27, 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

One in Five Acute MI Patients Drop Statins Within 2 Years

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

If You Don’t Take Your Stroke Meds, This App Will Tell on You

News Daily News

If You Don’t Take Your Stroke Meds, This App Will Tell on You

April 18, 2017

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

March 14, 2017

HDL Cholesterol

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

Rising Subdural Hematoma Rates Appear to Be Linked to Greater Use of Antithrombotics

News Daily News

Rising Subdural Hematoma Rates Appear to Be Linked to Greater Use of Antithrombotics

March 03, 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

News Conference News ISC 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

March 01, 2017

Restarting Oral Anticoagulation After Intracerebral Hemorrhage Tied to Better Outcomes

News Conference News ISC 2017

Restarting Oral Anticoagulation After Intracerebral Hemorrhage Tied to Better Outcomes

February 27, 2017

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.